N6-methyladenosine (m⁶A) is the most common RNA modification and has an important role in normal development and tumorigenesis. The abnormal expression of m⁶A regulators can lead to an imbalance in m⁶A levels in cancer cells, leading to the dysregulated expression of oncogenes and tumor suppressor genes that may contribute to cancer development, patient response to chemoradiotherapy, and clinical prognosis. Recent studies demonstrate that non-coding RNAs are involved in epigenetic modification of both DNA and RNA in tumor cells, and may also affect the development and progression of cancer by targeting m⁶A regulators. In this review, we describe the functional crosstalk between m⁶A and non-coding RNAs, particularly microRNA, long non-coding RNA, and circular RNA, and illustrate their roles in tumor regulation. Finally, we discuss the significance of non-coding RNA and m⁶A modification in the diagnosis, treatment, and prognosis of cancer patients, as well as potential future research directions.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: